Pharmacally
Biogen
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Biogen
Mergers & AcquisitionsBiogen to Acquire RayThera in Up to $1 Billion Deal, Expanding Immunology Pipeline with Phase 1-Ready AssetsBiogen will acquire RayThera in a deal valued up to $1 billion, adding a portfolio of anti-inflammatory small molecules to its immunology pipeline.Fact-Checked
Clinical TrialsBiogen Ends BIIB122 Program, Denali Continues Trial in LRRK2 CarriersBiogen and Denali Therapeutics will discontinue BIIB122 development in idiopathic Parkinson’s disease following negative Phase 2b LUMA results.Fact-Checked
Mergers & AcquisitionsBiogen Licenses Alloy AntiClastic ASO TechnologyAlloy Therapeutics has entered a collaboration and license agreement with Biogen to apply its AntiClastic ASO platform for developing antisense therapeutics against multiple undisclosed targets.Fact-Checked
Mergers & AcquisitionsBiogen Signs Deal with Alteogen to Develop Subcutaneous Versions of Two Biologic DrugsBiogen has secured exclusive rights to develop subcutaneous formulations of two biologic drugs using Alteogen’s ALT-B4 hyaluronidase technology, in a partnership that could reach up to $579 million…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.